Van ECK Associates Corp Grows Holdings in Zoetis Inc. $ZTS

Van ECK Associates Corp boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 269.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,387,059 shares of the company’s stock after purchasing an additional 1,740,113 shares during the quarter. Van ECK Associates Corp’s holdings in Zoetis were worth $300,340,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter valued at $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter valued at $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at $32,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Zoetis Stock Performance

Shares of ZTS opened at $79.51 on Friday. The company has a 50-day simple moving average of $96.94 and a 200-day simple moving average of $114.22. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $33.33 billion, a PE ratio of 13.19, a P/E/G ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $167.38.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus cut their price objective on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $133.92.

Insider Activity

In related news, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.